ReviewDrug, healthcare and patient safety2014
Temporomandibular disorders in patients with schizophrenia using antipsychotic agents: a discussion paper.
Review in Drug, healthcare and patient safety, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 11 citations in OpenAlex.
- Amisulpride augmentation therapy improves cognitive performance and psychopathology in clozapine-resistant treatment-refractory schizophrenia: a 12-week randomized, double-blind, placebo-controlled trial.Military Medical Research · 2022Trial
- Validity and reliability of the 8-item version of the jaw functional limitation scale (JFLS-8) in the Arabic language.Journal of oral & facial pain and headache · 2026Article
- Understanding Occlusion and Temporomandibular Joint Function Using Deep Learning and Predictive Modeling.Clinical and experimental dental research · 2024Review
- The Effect of Antipsychotics on Cognition in Schizophrenia-A Current Narrative Review.Brain sciences · 2024Review
- Genetically predicted major depression causally increases the risk of temporomandibular joint disorders.Frontiers in genetics · 2024Article
- Psychometric Properties of the Schizophrenia Oral Health Profile: Preliminary Results.International journal of environmental research and public health · 2021Article
- Minireview on the Connections between the Neuropsychiatric and Dental Disorders: Current Perspectives and the Possible Relevance of Oxidative Stress and Other Factors.Oxidative medicine and cellular longevity · 2020Review
- Advancements in temporomandibular joint total joint replacements (TMJR).Biomedical engineering letters · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients with psychiatric problems show a tendency to develop temporomandibular disorders (TMD). Particularly, patients with schizophrenia are quite likely to have signs and symptoms of TMD due to the impairment of their oral health, the use of antipsychotic drugs, and other general health problems. In nonschizophrenic populations, TMD have been considered as the main cause of nondental pain in the orofacial region, involving mechanisms associated with changes in masticatory activity at the cortical and neuromuscular levels. Individuals with schizophrenia do not usually complain of pain, and TMD is misdiagnosed in this population. In this paper, we aimed to review the clinical aspects of TMD in people with schizophrenia on antipsychotic drug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.